



FOR IMMEDIATE RELEASE

**April 1, 2009 -- Verrow Pharmaceuticals, Inc., Presents
to InvestMidwest Capital Conference**

LENEXA, KS -- Verrow Pharmaceuticals, Inc., presented today at the InvestMidwest Capital Conference, a forum where leading investors from around the Midwest gathered to see presentations from 44 competitively selected companies in the fields of life sciences, technology, and green energy.

Vernon Rowe, M.D., founder and CEO of Verrow, presented investment opportunities in the company. The company is focused initially on its lead product, Veropaque, an iodinated contrast agent which could make many procedures that require x-ray visualization of blood vessels or organs safer. The product, which uses Verrow's platform technology to protect the kidneys from contrast-induced acute kidney injury (CI-AKI), is most acutely needed in interventional cardiology procedures, where researchers have established a clear link between CI-AKI and significantly increased mortality rates.

As Verrow continues to gain exposure in the business community, officers are focused on aggressively pursuing Veropaque's path to FDA approval. Having demonstrated impressive results in preclinical studies, Verrow will have a preIND meeting with the FDA in April to discuss the clinical development program. Consulting on this program is Dr. Peter McCullough, an internationally recognized authority on the impact of kidney injury on cardiology outcomes.

ABOUT VERROW

Verrow Pharmaceuticals, Inc. (www.verrow.com), a drug development company founded in 2006, is building a portfolio of lead products based on proven drugs by making them less toxic, utilizing a proprietary platform technology.

Two pipeline products have already been discussed with the FDA in preIND meetings: Vertrexate, a novel treatment for secondary progressive multiple sclerosis (SPMS); and Verplatin, a safer formulation of a platinum-containing anti-cancer agent.

The modification of existing drugs allows regulatory approval through the abbreviated 505(b)(2) pathway, a cost- and time-saving strategy that has been validated by the FDA's response to Verrow's first two pre-IND submissions.